# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K193204   
B Applicant Precision BioLogic   
C Proprietary and Established Names CRYOcheck Chromogenic Factor Ⅷ   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>GGP</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 864.7290 - FactorDeficiency Test</td><td rowspan=1 colspan=1>HE - Hematology</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Clearance of a new device   
B Measurand: Factor Ⅷ activity $( \% )$   
C Type of Test: Quantitative chromogenic assay

III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below. B Indication(s) for Use:

CRYOcheck Chromogenic Factor Ⅷ is for clinical laboratory use in the quantitative determination of factor Ⅷ activity in $3 . 2 \%$ citrated human plasma. It is intended to be used in identifying factor Ⅷ deficiency and as an aid in the management of hemophilia A in individuals aged 2 years and older. For in vitro diagnostic use.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only

D Special Instrument Requirements:

Instrumentation Laboratory (IL) ACL TOP CTS Series and ACL TOP 50 CTS Series

# IV Device/System Characteristics:

# A Device Description:

CRYOcheck Chromogenic Factor Ⅷ is used for determination of FⅧ activity and contains the following four components:

<table><tr><td rowspan=1 colspan=1>Reagent Name</td><td rowspan=1 colspan=1>Format(per vial set; each boxcontains 4 vials sets)</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>Reagent 1</td><td rowspan=1 colspan=1>1 x 1.25 mL Frozen</td><td rowspan=1 colspan=1>Bovine FX and a fibrin polymerizationinhibitor, with activators and stabilizers.</td></tr><tr><td rowspan=1 colspan=1>Reagent 2</td><td rowspan=1 colspan=1>1 x 1.25 mL Frozen</td><td rowspan=1 colspan=1>Human FIIa, human FIXa, calciumchloride and phospholipids.</td></tr><tr><td rowspan=1 colspan=1>Reagent 3</td><td rowspan=1 colspan=1>1 x 1.25 mL Frozen</td><td rowspan=1 colspan=1>FXa substrate containing EDTA and athrombin inhibitor.</td></tr><tr><td rowspan=1 colspan=1>Diluent Buffer</td><td rowspan=1 colspan=1>1 x 7.0 mL Frozen</td><td rowspan=1 colspan=1>Tris buffer solution containing BSA and aheparin antagonist.</td></tr></table>

# B Principle of Operation:

The CRYOcheck Chromogenic FⅧ is a two-stage factor VIII (FVIII) assay. In the first stage, patient plasma (containing an unknown amount of functional FⅧ) is diluted with Diluent Buffer and combined with Reagents 1 and 2, containing Factors IXa and X, thrombin, calcium, and phospholipids. The FⅧ in the patient's plasma is activated and works in concert with FIXa to cause the activation of FX to FXa. Following an incubation period to allow activation of FX to FXa, the second stage of the assay occurs through the addition of the chromogenic FXa Substrate to this mixture. The FXa, present from the previous step, hydrolyzes the substrate into a peptide and p-Nitroaniline (pNA). The color produced by the release of pNA is measured spectrophotometrically at $4 0 5 \mathrm { n m }$ and is proportional to the Factor Ⅷ in the sample. FVIII results are reported in percent activity where $100 \%$ FVIII activity is equivalent to $1 . 0 \ : \mathrm { I U / m L }$ .

# V Substantial Equivalence Information:

A Predicate Device Name(s): Coatest Sp FⅧ

B Predicate 510(k) Number(s): K042576

# C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K193204</td><td colspan="1" rowspan="1">K042576</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">CRYOcheck ChromogenicFVIII</td><td colspan="1" rowspan="1">Coatest SP FVIII</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications ForUse</td><td colspan="1" rowspan="1">CRYOcheck ChromogenicFactor VIII is for clinicallaboratory use in thequantitative determination offactor VIII activity in 3.2%citrated human plasma. It isintended to be used inidentifying factor VIIIdeficiency and as an aid in themanagement of hemophilia Ain individuals aged 2 years andolder. For in vitro diagnosticuse.</td><td colspan="1" rowspan="1">Coatest SP FVIII is intendedfor photometric determinationof factor VIII activity incitrated plasma, such as whenidentifying factor VIIIdeficiency or monitoringpatients on replacementtherapy, as well as forpotency estimation of FVIIIconcentrates. For in vitrodiagnostic use.</td></tr><tr><td colspan="1" rowspan="1">Classification</td><td colspan="1" rowspan="1">Class Ⅱ</td><td colspan="1" rowspan="1">Class II</td></tr><tr><td colspan="1" rowspan="1">Type of Test</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Quantitative</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">Human Factor VIII activity</td><td colspan="1" rowspan="1">Human Factor VIII activity</td></tr><tr><td colspan="1" rowspan="1">Device Description</td><td colspan="1" rowspan="1">CRYOcheck ChromogenicFactor VIII is used fordetermination of FVIII activityand contains the following fourcomponents, packaged in glassvials and provided frozen topreserve the integrity of thecomponents:Reagent 1: Bovine FX and afibrin polymerization inhibitor,with activators and stabilizers.Reagent 2: Human FIIa,human FIXa, calcium chlorideand phospholipids.Reagent 3: FXa substratecontaining EDTA and athrombin inhibitor.</td><td colspan="1" rowspan="1">Coatest SP FVIII is amodified version of CoatestFactor VIII (K833892)reformulated to EuropeanPharmacopoeia Standards.Coatest SP FVIII is aphotometric assay containinga chromogenic substrate, S-2765, with EDTA added as apreservative, lyophilizedbovine factors IXa and Xwith bovine albumin added asa stabilizing agent. Thedevice also contains calciumchloride, Tris buffer stocksolution containing sodiumchloride, bovine serumalbumin with added</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Diluent Buffer: Tris buffersolution containing 1% BSAand a heparin antagonist.</td><td colspan="1" rowspan="1">antimicrobial in addition to amixture of highly purifiedsynthetic phospholipids.</td></tr><tr><td colspan="1" rowspan="1">Test Principle</td><td colspan="1" rowspan="1">In the presence of calcium andphospholipids, FX is activatedto factor Xa by FIXa. Thisgeneration is greatly stimulatedby FVIII, which may beconsidered as a cofactor in thisreaction. By using optimalamounts of Ca2+ andphospholipids and an excess ofFIXa and FX, the rate ofactivation of FX is solelydependent on the amount ofFVIII. FXa hydrolyses thechromogenic substrate S- 2765thus liberating thechromophoric group, pNA. Thecolor is then readphotometrically at 405 nm. Thegenerated FXa and thus theintensity of color areproportional to the FVIIIactivity in the sample.Hydrolysis of S-2765 bythrombin formed is preventedby the addition of the syntheticthrombin inhibitor, I- 2581,together with the substrate.</td><td colspan="1" rowspan="1">In the first stage of thechromogenic assay, testplasma (containing anunknown amount offunctional FVIII) is added toa reaction mixture comprisedof calcium, phospholipids,human purified thrombin andFIXa and bovine FX (Reagent1 and Reagent 2). Thismixture swiftly activatesFVIII to FVIIIa, which worksin concert with FIXa toactivate FX. When thereaction is stopped, FXaproduction is assumed to beproportional to the amount offunctional FVIII present inthe sample. The second stageof the assay is to measureFXa through cleavage of anFXa-specific peptidenitroanilide substrate (FXaSubstrate). P-nitroaniline isproduced, giving a color thatcan be measuredspectrophotometrically byabsorbance at 405 nm.</td></tr><tr><td colspan="1" rowspan="1">Expression ofResults</td><td colspan="1" rowspan="1">Quantitative; results areexpressed as percent activityinterpreted relative to acalibration curve.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument(s)</td><td colspan="1" rowspan="1">IL ACL TOP CTS Series andACL TOP 50 CTS Series</td><td colspan="1" rowspan="1">Manual method, IL ACL9000</td></tr><tr><td colspan="1" rowspan="1">Calibrator andcontrol plasmas</td><td colspan="1" rowspan="1">CRYOcheck Reference ControlNormalCRYOcheck Abnormal 1Reference ControlCRYOcheck Abnormal 2Reference ControlCRYOcheck Reference Control</td><td colspan="1" rowspan="1">HemosIL Normal Control(Assayed)HemosIL High AbnormalControl (Assayed)Calibration plasma calibratedagainst an InternationalStandard</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Normal, CRYOcheckAbnormal 1 Reference Control,and CRYOcheck Abnormal 2Reference Control are traceableto the WHO InternationalStandard for Factor VIII/VWF</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">≤70°C until expiration</td><td colspan="1" rowspan="1">28°C until expiration</td></tr><tr><td colspan="1" rowspan="1">Assay ReportableRange</td><td colspan="1" rowspan="1">0~200% FVIII activity</td><td colspan="1" rowspan="1">0-150% FVIII activity</td></tr><tr><td colspan="1" rowspan="1">Reference Range</td><td colspan="1" rowspan="1">43.2159.3% FVIII activity</td><td colspan="1" rowspan="1">Manual Method: 48.6126%Instrument Application: 55.4148.9%</td></tr><tr><td colspan="1" rowspan="1">Limit of Detection</td><td colspan="1" rowspan="1">0.5% FVIII activity</td><td colspan="1" rowspan="1">1% FVIII activity</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP07 $3 ^ { \mathrm { r d } }$ Edition, Interference Testing in Clinical Chemistry; Approved Guideline, Third Edition, April 2018.   
• CLSI EP06, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline, April 2003.   
• CLSI EP05-A3, Evaluation of Precision Performance of Quantitative Measurement Procedures; Approved Guideline, Third Edition, October 2014.   
• CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline, Second Edition, June 2012.   
• CLSI EP25-A, Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline, September 2009.   
• CLSI EP28-A3c, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, Third Edition, October 2010.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

1. Precision/Reproducibility:

a. Single-site Study:

This study was conducted at one internal site over 20 days with two runs per day and two replicates per run, for a total of 80 determinations per sample per lot. The study design included a single representative instrument model, three reagent lots, one normal and two abnormal reference controls, as well as five patient plasma samples representing very low, low, mid, normal and high levels of FⅧ activity. Precision estimates were calculated for each of the following variance components: within-run, between-run,

between-day, between-lot and total imprecision. The results for within-run and total imprecision for all lots combined are provided in the summary table below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Within-Laboratory</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal reference control</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>80.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>Abnormal 1 reference control</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>7.1</td></tr><tr><td rowspan=1 colspan=1>Abnormal 2 reference control</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>9.9</td></tr><tr><td rowspan=1 colspan=1>Plasma sample 1</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Plasma sample 2</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.4</td></tr><tr><td rowspan=1 colspan=1>Plasma sample 3</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Plasma sample 4</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>85.3</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>Plasma sample 5</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>152.1</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>3.8</td></tr></table>

# b. Multisite Study

This study was conducted at three sites over five days, with two runs per day and three replicates per run for a total of 90 determinations. The study design included two different representative instrument models (one instrument per site), three reagent lots, three operators, one normal and two abnormal reference controls, as well as three patient plasma samples representing very low, normal and high levels of FⅧ activity. Precision estimates were calculated for each of the following variance components: within-run, between-run, between-day, between-site and total imprecision. The results for total imprecision of all lots combined are provided in the summary table below.

<table><tr><td rowspan=2 colspan=1>Sample</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean (%)</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Site</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Normal reference control</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>80.3</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>Abnormal 1 reference control</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>25.4</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>Abnormal 2 reference control</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>9.6</td></tr><tr><td rowspan=1 colspan=1>Very low plasma sample</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Normal plasma sample</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>85.4</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>High plasma sample</td><td rowspan=1 colspan=1>270</td><td rowspan=1 colspan=1>156.9</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>11.4</td><td rowspan=1 colspan=1>7.3</td></tr></table>

# 2. Linearity/assay reportable range:

Linearity studies were performed following the CLSI EP06-A guideline using three reagent lots on a representative instrument model. Fifteen sample dilutions were prepared using a high FⅧ $( 2 6 0 \% )$ and a congenital FⅧ deficient plasma sample $( 0 \% )$ . Each dilution was tested in four replicates. Based on the results of the linearity study, the claimed linear range was determined to be $0 - 2 0 0 \%$ .

# 3. Analytical Specificity/Interference:

Interference studies were conducted based on the CLSI EP07-A2 guideline. The study design included a single reagent lot and one representative instrument model. Potentially interfering endogenous and exogenous substances were spiked into the test samples (one normal and one

abnormal reference control plasma sample) and the control samples. None of the substances in the following table (endogenous or exogenous substances) were found to lead to clinically significant interference.

<table><tr><td rowspan=1 colspan=1>Interfering Substance</td><td rowspan=1 colspan=1>Concentration Tested</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>≤ 500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>≤ 500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Unconjugated bilirubin</td><td rowspan=1 colspan=1>≤ 29 mg/dL</td></tr><tr><td rowspan=1 colspan=1>vWF</td><td rowspan=1 colspan=1>≤ 20 μg/mL</td></tr><tr><td rowspan=1 colspan=1>Unfractionated heparin</td><td rowspan=1 colspan=1>≤ 2 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Low molecular weightheparin</td><td rowspan=1 colspan=1>≤ 2 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Fondaparinux</td><td rowspan=1 colspan=1>≤ 1.25 mg/L</td></tr><tr><td rowspan=1 colspan=1>Lupus anticoagulant</td><td rowspan=1 colspan=1>≤ 1.8 dRVVT ratio</td></tr></table>

4. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# Traceability

Three levels of CRYOcheck Reference controls are prepared from human citrated plasma with three different concentrations of hemostatic parameters. CRYOcheck Reference Control Normal (K013708) was normal human citrated plasma while CRYOcheck Abnormal 1 Reference Control (K952624) and CRYOcheck Abnormal 2 Reference Control (K952624) were the citrated human plasma with hemostatic parameters values in the borderline pathological range $30 \%$ to $40 \%$ and $5 \%$ to $10 \%$ , respectively. Calibrator value assignments are traceable to the WHO International Standard for Factor VIII/VWF (6th IS Factor VIII/VWF Plasma, 07/316).

# Sample stability

Sample stability studies were performed to support the recommended storage and handling instructions found in the device labeling. Citrated plasma samples were tested after storage in the following temperature ranges, room temperature $( 1 5 - 2 5 ^ { \circ } \mathrm { C } )$ and below $- 7 0 \mathrm { { } ^ { \circ } C }$ . The study was performed using one reagent lot of CRYOcheck Chromogenic Factor Ⅷ on IL ACL TOP 300 and IL ACL TOP 700 (K160276) analyzers with four replicate measurements at each time point for each sample. The study data demonstrate that citrated plasma samples are stable for two hours when stored at room temperature $( 1 5 - 2 5 ^ { \circ } \mathrm { C } )$ , three months when stored at ${ < } . 7 0 { } ^ { \circ } \mathrm { C }$ , including up to two freeze thaw cycles.

# 5. Detection Limit:

The limit of blank (LoB), limit of detection (LoD), and limit of quantitation (LoQ) for the test system was determined following the CLSI EP17-A2 guideline. Each study design included three reagent lots and one representative instrument model.

The limit of blank (LoB) was determined using four plasma samples obtained from individuals with severe congenital Hemophilia A. Each sample was tested in three replicates on five different days on one representative instrument model for $\mathrm { n } { = } 1 5$ determinations per reagent lot. The sponsor determined the LoB to be $0 . 4 \%$ FⅧ activity.

The limit of detection (LoD) was determined using four plasma samples obtained from individuals with congenital Hemophilia A. Each sample was tested in three replicates on five different days on one representative instrument model for $\mathrm { n } { = } 1 5$ determinations per reagent lot. The sponsor determined the LoD to be $0 . 5 \%$ FVIII activity.

The limit of quantitation (LoQ) was determined using four plasma samples with low FⅧ activity at the following target concentrations: $0 . 4 \%$ FVIII, $0 . 4 \%$ FVIII, $0 . 5 \%$ FVIII and $0 . 5 \%$ FVIII. Each of the four plasma samples were tested in three replicates per day on five different days, for $\mathrm { n } { = } 1 5$ determinations per reagent lot. The sponsor determined the LoQ to be $0 . 5 \%$ FⅧ activity.

6. Assay Cut-Off: Not applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device:

The method comparison study was conducted using the CRYOcheck Chromogenic Factor Ⅷ on the Instrumentation Laboratory ACL TOP CTS and ACL TOP 750 CTS by testing $\mathrm { n } { = } 3 1 8$ clinical samples (citrated plasma) collected from the intended use population. Results from the CRYOcheck Chromogenic Factor Ⅷ were compared to results from the Instrumentation Laboratory Coatest SP FⅧ on the Instrumentation Laboratory ACL TOP 700. The following tables summarize the line equation from the Passing-Bablok regression analysis performed for the combined dataset and the absolute predicted bias.

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Pearson CorrelationCoefficient</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Intercept(95% CI)</td></tr><tr><td rowspan=1 colspan=1>318</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>1.041(1.027, 1.058)</td><td rowspan=1 colspan=1>0.720(0.252, 1.205)</td></tr></table>

<table><tr><td colspan="1" rowspan="1">%FVIII activity</td><td colspan="1" rowspan="1">AbsolutePredicted Bias(95% CI)</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">-1.11(-1.87, -0.35)</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">-0.81(-1.53, -0.08)</td></tr><tr><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">2.20(1.71, 2.69)</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">2.57(2.09, 3.06)</td></tr><tr><td>100</td><td>6.33 (5.51, 7.15)</td></tr><tr><td>150</td><td>10.09 (8.71, 11.47)</td></tr></table>

2. Matrix Comparison: Not applicable

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

The reference interval study was conducted at one laboratory site. The FⅧ activity of plasma samples collected from 120 normal, ostensibly healthy individuals $( \geq 1 8$ years) was tested by two operators using three lots of CRYOcheck Chromogenic Factor Ⅷ on an Instrumentation Laboratory ACL TOP CTS. The reference interval was established by calculating the nonparametric $9 5 \%$ confidence interval $( 2 . 5 ^ { \mathrm { t h } }$ to $9 7 . 5 ^ { \mathrm { t h } }$ percentiles). The calculated normal reference range for CRYOcheck Chromogenic Factor Ⅷ is $4 3 . 2 \mathrm { - } 1 5 9 . 3 \%$ .

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.